Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Shanghai University of Traditional Chinese Medicine | China

AUTHOR PROFILE

Scopus

📚 EARLY ACADEMIC PURSUITS

Xin Xin’s academic journey is rooted in the integration of Traditional Chinese Medicine (TCM) with Western medicine, particularly focusing on reproductive health and gynecology. He obtained a Bachelor of Science in Chinese Medicine from Shandong University of Traditional Chinese Medicine. His academic foundation continued to expand as he pursued an MD in Gynecology of Traditional Chinese Medicine, further honing his expertise in reproductive diseases. Xin is currently working towards his PhD in Clinical Chinese Medicine Integrated with Western Medicine at Shanghai University of Traditional Chinese Medicine, under the guidance of Advisor Jinfu Zhang.

💼 PROFESSIONAL ENDEAVORS

Xin Xin’s professional career is centered on bridging the gap between traditional and modern medical approaches. He is particularly involved in the clinical and mechanistic research of reproductive diseases, with a primary focus on polycystic ovary syndrome (PCOS). His work aims to enhance diagnostic methods and treatment approaches through a combined understanding of TCM and Western medicine. Xin has contributed significantly to clinical studies and investigations, with his academic path guided by prominent scholars in the field, including Dr. Fang Lian and Dr. Haicui Wu during his MD program at Shandong University.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER BIOMARKERS

Xin Xin’s research is notable for its emphasis on the pathogenesis, diagnosis, and treatment of reproductive diseases, with a particular focus on PCOS. He has undertaken several groundbreaking projects, one of which explores the expression of long non-coding RNAs (lncRNA) in follicular fluid exosomes of patients with obesity and PCOS using high-throughput sequencing technology. This research represents an effort to better understand the molecular mechanisms behind PCOS and to uncover novel biomarkers for early detection and intervention.

Another area of Xin’s research explores the role of Bone Morphogenetic Protein 6 (BMP6) in regulating Pentraxin 3 expression in human granulosa lutein cells in women with PCOS. His studies are pivotal in uncovering molecular markers and pathways that could lead to more effective therapeutic strategies.

🌟 IMPACT AND INFLUENCE

Xin Xin’s work has garnered attention within the scientific community due to his innovative approach of combining traditional Chinese medicine with Western medical techniques. His research aims to contribute to the development of a more holistic and comprehensive understanding of reproductive diseases. By investigating both the molecular and clinical aspects of PCOS, Xin is pushing boundaries in reproductive health research. His work has the potential to change how clinicians approach the treatment of polycystic ovary syndrome, a condition that affects millions of women worldwide.

📑 ACADEMIC CITES

Although his research is relatively recent, Xin Xin’s work is beginning to attract attention in the academic community. His publications on the expression of lncRNAs and BMP6 in PCOS are contributing to the growing body of knowledge on this common reproductive disorder. These publications are expected to increase in citations as they influence future studies and clinical approaches. His articles, including “Exploring lncRNA expression in follicular fluid exosomes of patients with obesity and polycystic ovary syndrome” (2024), and “Bone Morphogenetic Protein 6 Induces Downregulation of Pentraxin 3 Expression in Human Granulosa Lutein Cells in Women With Polycystic Ovary Syndrome” (2024), are already making a mark in reproductive health research.

🌱 LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Xin Xin is poised to continue his impactful contributions to the field of reproductive medicine. With a focus on integrating TCM with Western medical practices, his future research may lead to the development of novel therapeutic modalities for PCOS and other reproductive diseases. He is likely to remain an influential figure in the field of gynecology, particularly in areas that explore the intersections between traditional and modern approaches to healthcare. His research has the potential to influence both clinical practices and medical education, paving the way for new, more integrated methods of treating complex reproductive health conditions.

In the coming years, Xin Xin’s work will likely expand into further clinical trials and studies, contributing to the refinement of treatments for women with PCOS, and potentially providing a more personalized and effective approach to reproductive medicine globally.

✨Conclusion:

Xin Xin’s academic and professional journey stands as a testament to the growing importance of integrating traditional and modern medical practices in addressing complex health conditions. His dedicated research in reproductive medicine, particularly focusing on polycystic ovary syndrome (PCOS), has already made valuable contributions to understanding its pathogenesis and improving diagnostic and therapeutic methods. By exploring innovative molecular mechanisms and combining high-throughput sequencing technology with traditional Chinese medicine, Xin is laying the groundwork for a more holistic approach to treating reproductive diseases.

📊🔬NOTABLE PUBLICATION:
  • Reproductive outcomes of dual trigger with combination GnRH agonist and hCG versus trigger with hCG alone in women undergoing IVF/ICSI cycles: a retrospective cohort study with propensity score matching
    • Authors: Dong, L., Lian, F., Wu, H., Yu, X., Xin, X.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2022

 

  • The effect of large follicle puncture and aspiration on the outcomes of IVF-ET in patients with asynchronized follicles under the long GnRH-a protocol: a retrospective cohort study
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2023

 

  • Effect of human chorionic gonadotropin injection before frozen-thawed embryo transfer: A retrospective cohort study
    • Authors: Xin, X., Dong, L., Guan, L., Li, J., Lian, F.
    • Journal: Medicine (United States)
    • Year: 2023

 

  • Clinical Efficacy and Mechanism of Erzhi Tiangui Prescription in Treatment of Patients with Repeated Implantation Failure of Kidney Deficiency Syndrome Based on sPD-1 and Th17/Treg Cytokines
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: Chinese Journal of Experimental Traditional Medical Formulae
    • Year: 2023

 

  • Total knee arthroplasty in patients with Klippel Trenaunay syndrome and knee osteoarthritis: A case report and a literature review
    • Authors: Li, J., Lv, G., Han, Z., Xin, X.
    • Journal: Medicine (United States)
    • Year: 2024

Dr. Lei Xia | Theranostics | Best Researcher Award

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD 🧬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
📞 Phone: 18811177191
✉️ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes 🩻
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes 🧫
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes 🧪
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) 🌟
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) 🌟
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) 🌟
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund 🌟
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund 🌟
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital 🌟
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund 🌟
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

📊🔬Notable Publication:

 

 

 

 

Prof Dr. Rommel MarioRodriguez Burbano – Oncology and Precision Medicine – Best Researcher Award

Prof Dr. Rommel MarioRodriguez Burbano - Oncology and Precision Medicine - Best Researcher Award

Ophir Loyola Hospital - Brazil

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Rommel Mario Rodríguez Burbano began his academic journey by earning a degree in Biomedicine from the Federal University of Pará in 1989. He then pursued further education, completing his Master's (1993) and Ph.D. (1998) in Biological Sciences (Genetics) from the Faculty of Medicine of Ribeirão Preto, University of São Paulo.

PROFESSIONAL ENDEAVORS

After completing his formal education, Rommel embarked on a diverse and impactful professional career. He conducted post-doctoral research in Morphology at the Discipline of Genetics, Escola Paulista de Medicina, Federal University of São Paulo in 2005. Currently, he holds the prestigious position of Full Professor at the Federal University of Pará.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Rommel Mario Rodríguez Burbano's contributions to academia are significant and multifaceted. His research primarily focuses on Human Genetics, Cell Biology, and Oncology. Throughout his career, he has demonstrated a keen interest in understanding molecular mechanisms underlying diseases, particularly cancer.

IMPACT AND INFLUENCE

Rommel's work has had a profound impact on the scientific community. His extensive publication record, comprising 296 scientific articles in specialized journals, one book, and seven book chapters, reflects his dedication to advancing knowledge in his field.

ACADEMIC CITATIONS

Rommel's research output has garnered considerable attention, as evidenced by his numerous academic citations. His work is widely recognized and cited by peers, contributing significantly to the advancement of scientific knowledge.

LEGACY AND FUTURE CONTRIBUTIONS

As a mentor and supervisor, Rommel has played a pivotal role in shaping the next generation of scientists. He has supervised a total of 44 master's theses, 41 doctoral theses, and mentored five postdoctoral fellows. His legacy extends beyond his own research contributions, influencing the work of numerous scholars who have benefited from his guidance and expertise.

HIGHLIGHTS

Rommel currently serves as the Coordinator of the Molecular Biology Laboratory at Hospital Ophir Loyola in Belém, Pará, indicating his leadership in translational research.He holds the Process and Molecular Biomarker patent, demonstrating his innovative approach to addressing scientific challenges.Rommel's involvement in editorial boards of 12 scientific journals and his role as a reviewer for numerous scientific publications underscore his commitment to peer-reviewed research and quality scholarship.

NOTABLE PUBLICATIONS

Homocystein, Vitamin B12 and Folic Acid as Screening Biomarkers in Early Diagnosis and Gastric Cancer Monitoring.  2024

Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials. 2024

Molecular Profile of Variants Potentially Associated with Severe Forms of COVID-19 in Amazonian Indigenous Populations. 2024 (1)

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. 2024

PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia. 2023